TAMPA, Fla., March 28, 2024 — Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced its schedule of research presentations at the American Association for Cancer Research (AACR) annual meeting in San Diego, California, April 5-10, 2024. The seven abstracts, which are a combination of oral and poster presentations, will be presented by researchers from institutions within the Oncology Research Information Exchange Network® (ORIEN), a research consortium administered by Aster Insights. All abstracts utilize data from ORIEN and Aster Avatar, the best-in-class, deepest multimodal dataset for discovery research in oncology.
The abstracts cover a broad range of research across several cancer types, including predictors of response to immunotherapy, the role of the tumor microbiome in patient outcomes, and the study of cancer in minority patient populations. Several of the presentations are ORIEN® intermember studies developed by the consortium’s research interest groups, which are designed to increase multidisciplinary, collaborative research among premier national cancer centers. Additionally, most of the abstracts include co-investigators from Aster Insights’ scientific leadership, reflecting the unique roles of both the company and ORIEN® in driving critical cancer discovery.
“There is no better demonstration of the versatility of Aster Insights and ORIEN than the selection of abstracts that will be presented at AACR this year,” said Dr. Anand Shah, CEO of Aster Insights. “The breadth of these investigations is a testament to the impact we have by bringing together the best expertise in cancer research to unlock new treatments and cures.”
Official schedule of Aster Insights’ presentations at AACR:
- Tarhini, A.A. Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy (abstract 71/7)
Poster Presentation: Sunday, April 7, 2024, 1:30 PM – 5:00 PM
Section 3
Session PO.IM01.01 – Biomarkers, Immune Monitoring, and Immune Assays - Grencewicz, D. Gavage with Candida albicans leads to fungal colonization of colorectal tumors and decreased response to radiotherapy (abstract 1282)
Oral Presentation: Sunday, April 7, 2024, 4:05 PM – 4:20 PM
Room 16 – Convention Center Mezzanine Level
Session MS.TB11.01 – Microbes and Tumors: Time for Mechanisms - Obermeyer, A. Analysis of clonal heterogeneity within paired primary and metastatic tumor samples of patients with solid tumors and implications for neoantigen-based personalized cancer vaccines (abstract 3886)
Oral Presentation: Monday, April 8, 2024, 2:35 PM – 2:50 PM
Room 6 CF – Convention Center Upper Level
Session MS.CL10.01 – Application of Real-World Evidence to Cancer Care - Soupi, A.C. Genomic landscape and estimation of immune infiltration of soft tissue sarcoma histology subtypes from the ORIEN network (abstract 3928)
Oral Presentation: Monday, April 8, 2024, 2:35 PM – 2:50 PM
Room 31 – Convention Center Upper Level
Session MS.MCB08.01 – Advances in Cancer Genomics: Carcinogenesis, Tumor Evolution, and Heterogeneity - Villarreal Velazquez, E.I. Multi-omics characterization of molecular features and global-local genomic ancestry analysis of colorectal cancer in Hispanic-Latinos (abstract 3932) Oral Presentation: Monday, April 8, 2024, 3:35 PM – 3:50 PM
Room 31 – Convention Center Upper Level
Session MS.MCB08.01 – Advances in Cancer Genomics: Carcinogenesis, Tumor Evolution, and Heterogeneity - Garay Raygoza, J. Tumor gene expression patterns affecting response to BCl-2 inhibitor venetoclax in acute myeloid leukemia (abstract 5852/28)
Poster Presentation: Tuesday, April 9, 2024, 1:30 PM – 5:00 PM
Section 23
Session PO.ET03.07 – Drug Resistance 3: Regulation of Gene Expression - Chan, C.H.F. Epithelial-mesenchymal-
transition gene signature changes and poor oncological outcome in Candida-positive pancreatic ductal adenocarcinoma (abstract 7615/9) Poster Presentation: Wednesday, April 10, 2024, 9:00 AM – 12:30 PM
Section 45
Session PO.CL01.13 – Predictive Biomarkers 7
“Fostering a rich culture of collaboration with multidisciplinary researchers is fundamental to the work Aster Insights has led for 10 years together with ORIEN,” said Michelle Churchman, PhD, Scientific Director at Aster Insights. “This spirit of cooperation makes ORIEN truly unique in oncology, and we look forward to sharing our work with the broader cancer research community at AACR.”
Aster Insights leadership will be attending AACR. Please contact us to request a meeting.
About Aster Insights
Aster Insights is the leading provider of scientific and clinical intelligence for oncology discovery. We partner with drug, biologics, diagnostics, and medical device developers to accelerate oncology product discovery and development. Aster Insights leads the Oncology Research Information Exchange Network® (ORIEN), a consortium of the nation’s leading cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. Together, we are changing the way cancer is studied, treated, and prevented. Learn more at www.AsterInsights.com and follow us on LinkedIn and Twitter.
